The company said revenues in its diagnostics business unit rose 62 percent during the quarter.
The company plans to launch the system this summer in Europe, aiming to broaden cell-free DNA screening for trisomy 21, 18, and 13.
The suit alleges that Natera's Panorama test infringes US Patent No. 9,493,831 patent, which covers sequencing library preparation methods applied to maternal blood samples.
In Q4 Natera tallied revenues of $53.8 million compared to $49.3 million a year ago, falling short of the consensus Wall Street estimate of $57.1 million.
The company agreed to settle a lawsuit alleging it improperly billed government health plans for its genetic tests.
The company is now seeking commercial partners in Brazil to make the Iona test available in the country.
The goal is to generate clinical outcome and economic data that will make the case to payors to cover NIPT for average-risk pregnancies.
Illumina plans to develop clinical-grade products and expects that reimbursement and regulatory trends will further drive growth of its technology in the clinic.
A jury agreed that Ariosa's noninvasive prenatal test infringed several claims in two patents held by Illumina.
Premaitha had been sued by Illumina for allegedly infringing on five patents related to noninvasive prenatal testing with its Iona test.